Cor­re­vio is putting it­self up on the auc­tion block af­ter FDA re­view pan­el points to an­oth­er re­jec­tion

For 13 years, the Cana­di­an biotech Cor­re­vio tried to get the FDA to ac­cept a heart drug since aban­doned by Mer­ck and Astel­las. Yes­ter­day, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.